Peptic ulcer of the stomach and duodenum. Reflux oesophagitis. Zollinger-Ellison syndrome and other conditions associated with excessive secretion of hydrochloric acid.
Composition:
1 vial contains 40 mg pantoprazole.
Action:
A drug that inhibits the secretion of hydrochloric acid in the parietal cells of the stomach as a result of selective blocking of H activity+/ K+-ATP-azy (the so-called proton pump). The effect of the drug depends on the dose and leads to inhibition of both basal secretion and stimulated secretion (regardless of the type of stimulus). It reduces the acidity of gastric contents and, secondarily, in a reversible manner, increases gastrin secretion to an extent proportional to the decrease in acidity. Pantoprazole is approximately 98% bound to plasma proteins. It is metabolized in the liver, excreted in about 80% by the kidneys in the form of metabolites, the remaining part is excreted in the faeces. T0,5 in the elimination phase it is about 1 hour.
Contraindications:
Hypersensitivity to the components of the preparation.
Precautions:
In patients with severe hepatic impairment, liver enzymes should be monitored regularly - if their activity increases, treatment should be discontinued. The concomitant use of pantoprazole with atazanavir is not recommended. There are no data on the use of pantoprazole in children, therefore it is not recommended for patients under 18 years of age.
Pregnancy and lactation:
During pregnancy and breastfeeding, use only if the expected benefit to the mother outweighs the potential risk to the fetus or fed child.
Side effects:
Common: thrombophlebitis at the injection site. Uncommon: sleep disturbances, headache and dizziness, epigastric pain, diarrhea, nausea, vomiting, abdominal fullness and bloating, constipation, dry mouth, epigastric pain and discomfort, increased liver enzymes (transaminases, γ -glutamyl transpeptidases), skin rash / eczema, skin eruptions, pruritus, hip fracture, carpal or spinal bones (with prolonged use), weakness, fatigue, malaise. Rare: agranulocytosis, hypersensitivity (including anaphylactic reactions and anaphylactic shock), hyperlipidemia and increased lipids (triglycerides, cholesterol), changes in body weight, depression (and all agitations), taste disturbances, blurred vision, blurred vision, increased bilirubin, urticaria, angioneurotic edema, joint pain, muscle pain, gynecomastia, elevated body temperature, peripheral edema. Very rare: thrombocytopenia, leukopenia, pancytopenia, confusion (and all agitations). Frequency unknown: hyponatraemia, hypomagnesaemia (with long-term use), hypocalcaemia, hypokalaemia, hallucinations, confusion (especially in predisposed patients, as well as worsening of these symptoms in case of their previous occurrence), paresthesia, liver cell damage, jaundice, hepatic cell failure, syndrome Stevens-Johnson, toxic epidermal necrolysis, erythema multiforme, hypersensitivity to light, muscle spasms, interstitial nephritis (with the possibility of renal failure). The use of pantaprazole may lead to a slightly higher risk of gastrointestinal infections caused by bacteria such asSalmonellaandCampylobacterorClostridium difficile.
Dosage:
Intravenously. Peptic ulcer of the stomach and duodenum, reflux oesophagitis: 40 mg daily. Zollinger-Ellison syndrome and other diseases associated with excessive secretion of hydrochloric acid: initially 80 mg, then individually. Daily doses greater than 80 mg should be given in two divided doses. Doses above 160 mg / day should not be used over a long period. In the event that a rapid inhibition of acid secretion is necessary, the initial dose of 2 x 80 mg of the preparation in most patients is sufficient to reduce the amount of secreted acid to the desired range within 1 h. In patients with severe hepatic impairment, the daily dose should be reduced to 20 mg. The contents of the vial should be dissolved in 10 ml of 0.9% NaCl.The solution thus prepared may be administered directly or after mixing with 100 ml of 0.9% NaCl solution or 5% Glucose solution. The duration of the infusion: 2-15 min. The solution should be used within 12 hours. The preparation is recommended only when oral pantoprazole can not be used. You should go to oral therapy as soon as possible.
(C)
